Effect of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure

Minerva Cardioangiologica

Volumn 51, Issue 2, 2003, Pages 143-154

  Khattar, R S ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adrenergic beta antagonists; Angiotensin converting enzime inhibitors; Congestive; Heart failure; Therapy; Ventricular remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; MITRAL VALVE REGURGITATION; MOLECULAR MECHANICS; PATIENT SELECTION; REVIEW; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 0038690110     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88-92.
3. Erlebacher JA, Weiss JL, Eatton LW, Kallman C, Weisfeldt ML, Buckley BH. Late effects of acute infarct dilation on heart size: a two-dimensional echocardiographic study. Am J Cardiol 1982;49:1120-6.
4. Cohn J. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504-7.
5. Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989;13:311-5.
6. Kurrelmeyer K, Kalra D, Bozkurt B, Wang F, Dibbs Z, Seta Y et al. Cardiac remodeling as a consequence and cause of progressive heart failure. Clin Cardiol 1998;21 Suppl. I:14-9.
7. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohimeyer TJ, Quaife RA et al. Changes in gene expression in the intact human heart. Down-regulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997;100:2315-24.
8. Schaper J, Froede R, Hein ST, Buck A, Hashizume H, Speiser B et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83:504-14.
9. Buckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85: 1046-55.
10. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
11. Davies CH, Daria K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995;92: 2540-9.
12. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
13. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
14. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98:1329-34.
15. Missov E, Calzolari C, Pau B. Circulating cardiac troponin-I in severe congestive heart failure. Circulation 1997;96:2953-8.
16. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley JA III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in left ventricular myocardium from patients with end stage heart failure. Circulation 1998;97:1708-15.
17. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996;63:185-98.
18. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995;27: 291-305.
19. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett CJ, Cruickshank JM et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20:3-16.
20. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin - aldosterone system. Circulation 1991;83:1849-65.
21. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960;69:370-82.
22. Glower DD, Spratt JA, Snow ND Kabas JS, Davis JW, Olsen CO et al. Linearity of the Frank Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 1985;71:994-1009.
23. Eichorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart - a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
24. Vatner SF. Reduced subendocarial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988;62:94E-8E.
25. Shannon RP, Komamura K, Shen YT, Bishop SP, Vatner SF. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing induced heart failure. Am J Physiol 1993;265:H801-9.
26. Sabbah HN, Goldstein S. Ventricular remodeling: consequences and therapy. Eur Heart J 1993;14 Suppl C: 24-9.
27. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-8.
28. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76: 44-51.
29. Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.
30. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vivo. Cell 1993; 75:977-84.
31. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH et al. Strech-induced programmed myocyte cell death. J Clin Invest 1995;96:2247-59.
32. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2 to Bax protein ratio in the cell. J Clin Invest 1998;101: 1326-42.
33. Henegar JR, Brower GL, Kabour A, Janacki JS. Catecholamine response to chronic angiotensin II infusion and its role in myocyte and coronary vascular damage. Am J Physiol 1995;269:H1564-9.
34. Pfeffer JM, Pfeffer MA, Brawnwald E. Influence of chronic captropril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
35. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989;64:330-7.
36. Litwin SE, Litwin CM, Raya TE, Warner AL, Goldman S. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition. Circulation 1991; 83:1028-37.
37. Katz A. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994;121:363-71.
38. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-6.
39. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet 1991;337:872-6.
40. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effect of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS - II). N Engl J Med 1992;327:678-84.
41. Pfeffer MA, Braunwald E, Moye L, Basta L, Brown Jr EJ, Cuddy TE et al. Effect of captropril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
42. AIRE study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-8.
43. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
44. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
45. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al., A comparison of enalapril with hydralazine - isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;325:303-10.
46. SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
47. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al. Long term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic review of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
48. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
49. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D et al. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8.
50. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D et al. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long term progression of left ventricular dilatation in patients with left ventricular systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993;88:2277-83.
51. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C et al. Effects of long term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction - results of the SOLVD echocardiographic substudy. Circulation 1995;91:2573-81.
52. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
53. Pepine CJ. Potential role of angiotensin converting enzyme inhibition in myocardial ischaemia and current clinical trials. Clin Cardiol 1997;20 (II Suppl 2):II58-64.
54. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
55. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, Defreyte G et al. Effects of chronic beta-adrenergic blockage on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-48.
56. Waagstein F, Hjalmarson A, Varnsuskas, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1995;37:1022-36.
57. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
58. Ikram H, Fitzpatrick D. Double blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981;2:490-3.
59. Currie PJ, Kelly MJ, Middlebrook K, Federman J, Sainsbury E, Ashley J et al. Acute intravenous and sustained oral treatment with the beta-1 agonist prenalterol in patients with severe cardiac failure. Br Heart J 1984;51:530-8.
60. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J-P. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled randomized trials. Circulation 1998;98:1184-91.
61. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):VI 40-8.
62. Eichorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA et al. Effect of metoprolol on myocardial function and energetics in patients with non-ischaemic dilated cardiomyopathy: a randomized double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
63. Eichorn EJ, Bedotto JB, Malloy CR, Hatfield BT, Deitchman D, Brown M et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in haemodynamic, contractile and diastolic performance with bucindolol. Circulation 1990;82:473-83.
64. Bristow MR. Carvedilol treatment of chronic heart failure: a new era. Heart 1998;79 Suppl. 2:S31-4.
65. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise haemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24: 1678-87.
66. Metha M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure. A prospective randomised, double-blind comparison of the long term effects of metoprolol versus carvedilol. Circulation 2000;102: 546-51.
67. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen deposition post-infarction. J Am Coll Cardiol 2000;36: 276-81.
68. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
69. Krum H, Sackner-Bernstein JD, Goldmsith RL, Kukin ML, Schwartz B, Penn J et al. Double-blind placebo-controlled study of the long term efficacy of carvedilol in patients with severe chronic hart failure. Circulation 1995;92:1499-506.
70. Bristow M, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
71. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldsher DA, Freeman I et al. Double-blind placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94:2793-9.
72. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
73. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
74. Copomolla S, Febo O, Gynemmi M, Ricardi G, Opasich C, Caporotondi A et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000; 139:596-608.
75. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
76. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
77. CIBIS-II Study Group. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
78. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999;353:2001-7.
79. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
80. Khattar RS, Senior R, Soman P, van der Does R, Lahiri A. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001;42:704-13.
81. Remme WJ, CARMEN Steering Committee and Investigators. The carvedilol and ACE-inhibitor remodelling heart failure evaluation trial (CARMEN) - rationale and design. Cardiovasc Drugs Ther 2001;15:69-77.
82. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-19.
83. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
84. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.